NCT00267267终止3 期
Phase 3, Open-Label, Multi-Center, Double-Blind, Randomized, Parallel Group Study Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin, Administered Once Daily (QD) Compared to Fixed Combination Ezetimibe/Simvastatin for 6 Weeks in Subjects With Dyslipidemia.
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 发起方
- Pfizer
- 入组人数
- 1,784
- 试验地点
- 124
- 主要终点
- Percent change in LDL-C and HDL-C from baseline, after six weeks of treatment.
研究概览
简要总结
The Torcetrapib project was terminated on December 2, 2006 due to safety findings.
Cholesterol levels will be measured over six weeks in subjects being treated with two different kinds of combination cholesterol medications to see how the different treatments compare to one another.
详细描述
For additional information please call: 1-800-718-1021
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Specific LDL-C levels based on CHD risk after a six-week washout period.
排除标准
- •Women who are pregnant or lactating, or planning to become pregnant.
- •Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors.
- •Subjects requiring systemic steroids
- •Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluation of response, or render unlikely that the subject would complete the study.
结局指标
主要结局
Percent change in LDL-C and HDL-C from baseline, after six weeks of treatment.
次要结局
- Changes in other lipid parameters and other biomarkers.
研究者
研究点 (124)
Loading locations...
相似试验
已完成
3 期
A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol.HypercholesterolemiaDyslipidemiaHyperlipidemiaNCT00267254Pfizer640
终止
3 期
A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031).HypercholesterolemiaDyslipidemiaHyperlipidemiaNCT00267280Pfizer640
终止
3 期
Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder.Hyperlipoproteinemia Type IIINCT00145431Pfizer41
已完成
3 期
Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial HypercholerolemiaHypercholesterolemia, FamilialHyperlipidemiaNCT00134485Pfizer400
已完成
3 期
A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart DiseaseCoronary DiseaseCoronary ArteriosclerosisHyperlipidemiaNCT00134173Pfizer1,100